Jump to ContentJump to Main Navigation

Open Medicine

formerly Central European Journal of Medicine

1 Issue per year


IMPACT FACTOR 2014: 0.153
5-year IMPACT FACTOR: 0.183

SCImago Journal Rank (SJR): 0.141
Source Normalized Impact per Paper (SNIP): 0.163

Open Access
VolumeIssuePage

Issues

Intensive treatment of persistent microalbuminuria: determinants of treatment resistance

1133Cátedra de Riesgo Cardiovascular, Facultad de Medicina Universidad de Salamanca, Salamanca, Spain

2133Centro de Salud Mérida Norte, Mérida, Spain

3133Centro de Salud Jose Maria Alvarez, Don Benito, Spain

4133Centro de Salud Ciudad Jardin, Badajoz, Spain

5133Centro de Salud Villanueva de la Serena, La Serena, Chile

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citation Information: Open Medicine. Volume 8, Issue 3, Pages 302–309, ISSN (Online) 2391-5463, DOI: 10.2478/s11536-012-0133-6, April 2013

Publication History

Published Online:
2013-04-17

Abstract

Keywords: Microalbuminuria; Hypertension; Remission; Response to treatment

  • [1] Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997; 157:1413–1418. http://dx.doi.org/10.1001/archinte.1997.00440340025002 [CrossRef]

  • [2] Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS Group: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225–232 http://dx.doi.org/10.1046/j.1523-1755.2003.00712.x [CrossRef]

  • [3] Mogensen CE: Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254:45–66 http://dx.doi.org/10.1046/j.1365-2796.2003.01157.x [CrossRef]

  • [4] Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421–426 http://dx.doi.org/10.1001/jama.286.4.421 [CrossRef]

  • [5] Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35:898–903 http://dx.doi.org/10.1161/01.HYP.35.4.898 [CrossRef]

  • [6] Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325–1333 http://dx.doi.org/10.1097/00004872-199816090-00014 [CrossRef]

  • [7] Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777–1782 http://dx.doi.org/10.1161/01.CIR.0000031732.78052.81 [CrossRef]

  • [8] Robles NR, Mena C, Velasco J, Angulo E, Garrote T, Garcia Gallego F, en representación de los investigadores del estudio MICREX Riesgo cardiovascular asociado a microalbuminuria en pacientes diabéticos y en pacientes con hipertensión arterial. Med. Clin. (Barc.). 2008;130: 206–209 http://dx.doi.org/10.1157/13116172 [CrossRef]

  • [9] The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289:2560–2572

  • [10] Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105–1187 http://dx.doi.org/10.1097/HJH.0b013e3281fc975a [CrossRef]

  • [11] Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS: Long-term effects of angiotensinconverting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57:590–600 http://dx.doi.org/10.1046/j.1523-1755.2000.00879.x [CrossRef]

  • [12] Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870–878 http://dx.doi.org/10.1056/NEJMoa011489 [CrossRef]

  • [13] Viberti G, Wheeldon NM, MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672–678 http://dx.doi.org/10.1161/01.CIR.0000024416.33113.0A [CrossRef]

  • [14] Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:2285–2293 http://dx.doi.org/10.1056/NEJMoa021835 [CrossRef]

  • [15] Robles NR, Velasco J, Mena C, Angulo E, Garrote T, en representación de los investigadores del estudio MICREX Microalbuminuria en pacientes diabéticos y en pacientes con hipertensión arterial: estudio de una cohorte de 979 pacientes. Med. ClÍn. (Barc). 2006; 127: 761–764 http://dx.doi.org/10.1157/13095811

  • [16] Robles NR, Velasco J, Espinosa J, Mena C, Angulo E, on behalf of the MICREX Group Investigators. Persistent microalbuminuria after treatment with renin-angiotensin axis blockers; causes and results of treatment intensification. J. Renin Angiotensin System. 2011; 12: 333–339 http://dx.doi.org/10.1177/1470320310374215 [CrossRef] [Web of Science]

  • [17] Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).J Hypertens. 2007; 25: 1105–1187 http://dx.doi.org/10.1097/HJH.0b013e3281fc975a

  • [18] American Diabetes Association. Standards of Medical Care in Diabetes-2007. Diabetes Care. 2007; 30(Suppl. 1); S4–S41 http://dx.doi.org/10.2337/dc07-S004 [CrossRef]

  • [19] The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560–2572

  • [20] Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicotella C, Viazzi F et al. The deletion polymorphism of the angiotensin-1 converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7:2250–2258

  • [21] Deckert T, Kofoed-Enevoldsen A, Videl P, Norgaard K, Andreasen HB, Feldt-Rasmussen B. Size and charge selection in glomerular ®ltration in Type 1 diabetic patients with and without albuminuria. Diabetologia 1993; 36: 244–251 http://dx.doi.org/10.1007/BF00399958 [CrossRef]

  • [22] Bianchi S, Bigazzi R, Campese VM, Microalbuminuria in Essential Hypertension: Significance, Pathophysiology, and Therapeutic Implications. Am J Kidney Dis. 1999; 34: 973–995 http://dx.doi.org/10.1016/S0272-6386(99)70002-8 [CrossRef]

  • [23] Gosling P, Beevers DG. Urinary albumin excretion in the general population. Clin Sci 1989; 76: 39–42 [Web of Science]

  • [24] West JN, Gosling P, Dimmit SB, Littler WA. Nondiabetic microalbuminuria in clinical practice and its relationship to posture, exercise and blood pressure. Clin Sci 1991; 81: 373–377

  • [25] Rogus JJ, Warram JH, Krolewski AS. Genetic studies of late diabetic complications. The overlooked importance of diabetes duration before complication onset. Diabetes 2002; 51: 1655–1662 [CrossRef]

  • [26] Tarnow L. Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors. Danish Med Bull 2002; 49: 19–42

  • [27] Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254: 45–66 http://dx.doi.org/10.1046/j.1365-2796.2003.01157.x [CrossRef]

  • [28] Guidelines Committee of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011–1053, 2003

  • [29] Böhm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens. 2008; 26: 18–25 http://dx.doi.org/10.1097/HJH.0b013e3282f05c8a [CrossRef]

  • [30] Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993; 21:810±815 http://dx.doi.org/10.1161/01.HYP.21.6.810 [CrossRef]

  • [31] Anderson S, Diamond JR, Karnovsky MJ, Brenner BM. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic sÍndrome. J. Clin. Invest. 1988; 82: 1757–1768 http://dx.doi.org/10.1172/JCI113789 [CrossRef]

  • [32] Anderson S, Brenner BM. Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. Am J Hypertens. 1988; 1(4 Pt 2):380S–383S

  • [33] Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest. 1988; 82:322–330 http://dx.doi.org/10.1172/JCI113590 [CrossRef]

  • [34] Lax DS, Benstein JA, Tolbert E, Dworkin LD. Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int. 1992; 41: 1527–1534 http://dx.doi.org/10.1038/ki.1992.222 [CrossRef]

  • [35] Hsueh WA, Do YS, Anderson PW, Law RE. Angiotensin II in cell growth and matrix production. Adv Exp Med Biol. 1995; 377: 217–223 http://dx.doi.org/10.1007/978-1-4899-0952-7_12 [CrossRef]

  • [36] Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, Katayama S, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia. 2010; 53: 49–57 http://dx.doi.org/10.1007/s00125-009-1577-3 [Web of Science] [CrossRef]

  • [37] Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002; 347: 797–805 http://dx.doi.org/10.1056/NEJMoa013410 [CrossRef]

  • [38] Afsar B, Sezer S, Elsurer R, Ozdemir FN. Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit. 2007; 12: 133–139 http://dx.doi.org/10.1097/MBP.0b013e3280b08379 [CrossRef] [Web of Science]

  • [39] Hermida RC, Ayala DE, Mojón A, Fernández JR. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens. 2008; 21: 948–954 http://dx.doi.org/10.1038/ajh.2008.216 [Web of Science] [CrossRef]

  • [40] Hermida RC, Calvo C, Ayala DE, Fernández JR, Covelo M, Mojón A, López JE. Treatment of nondipper hypertension with bedtime administration of valsartan. J Hypertens. 2005; 23: 1913–1922 http://dx.doi.org/10.1097/01.hjh.0000182522.21569.c5 [CrossRef]

  • [41] Kawai T, Ohishi M, Kamide K, Nakama C, Onishi M, Ito N,et al. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertens Res. 2012 Oct 18. doi: 10.1038/hr.2012.162. [Epub ahead of print] [Web of Science] [CrossRef]

  • [42] Ulusoy S, Ozkan G, Konca C, Kaynar K. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability. Hypertens Res. 2012; 35: 1111–1117 http://dx.doi.org/10.1038/hr.2012.95 [CrossRef]

Comments (0)

Please log in or register to comment.